For more than two decades, LUNGevity Foundation has been a leader in advancing lung cancer research. Since 2002, we have invested $55+ million in more than 200 research projects, helping to build a robust pipeline of discoveries in early detection, treatment innovation, and health equity. Once again, LUNGevity is ready to open our annual grant cycle in 2026 with five research programs designed to address the most pressing challenges in lung cancer care. In addition, these grants ensure the next generation of researchers is poised to continue making progress for everyone affected by this

Lung cancer research was in the spotlight at the European Society for Medical Oncology (ESMO) meeting held October 17-21, 2025, in Berlin, Germany. With approximately 30,000 attendees from over 100 countries, this meeting gathered an international audience of clinicians, researchers, patient advocates, and representatives from the healthcare industry to discuss cutting-edge cancer research and share practice-changing clinical trial data. We saw data from studies that aim to build upon existing treatments, to optimize combination approaches, and to address some of the unmet needs of people

This special edition of the Small Cell SMASHERS features Misty Shields, MD, PhD, as a guest instead of her usual role as host. Dr. Shields is a thoracic medical oncologist, assistant professor of clinical medicine, adjunct assistant professor of medical and molecular genetics, and associate member of experimental and developmental therapeutics at Indiana University School of Medicine and Indiana University Health Physicians. Dr. Shields discusses her American Society of Clinical Oncology (ASCO) Career Development Award study for lurbinectedin and the role of predictive biomarkers. Moderated by

In November, Trudy Oliver, PhD, professor of pharmacology and cancer biology at Duke University School of Medicine and Duke Cancer Institute, discussed the origins of small cell lung cancer (SCLC) and its impact on plasticity. Moderated by Dr. Misty Shields, Indiana University School of Medicine, and LUNGevity’s Ann Fish-Steagall, SVP of Patient Services and Health Care Delivery, this monthly virtual series highlights the latest discoveries and breakthroughs for SCLC.

Over the past twenty years, lung cancer research and care have entered a new era. One filled with hope, innovation, and progress that is transforming what it means to face a lung cancer diagnosis. From groundbreaking early detection efforts to life-extending treatments, each step forward represents years of collaboration between researchers, patients, and others in the lung cancer community. Today, LUNGevity celebrates five exciting areas of progress that highlight the incredible strides made through sustained lung cancer research. 1. The Precancer Genome Atlas: Stopping Lung Cancer Before It

In this Facebook Live on Tuesday, October 14, Toby Campbell, MD, MS, thoracic medical oncologist and chief of palliative care at the University of Wisconsin Health, discussed palliative care in small cell lung cancer. Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.

In this Facebook Live from September 30, Sonam Puri, MD, Department of Thoracic Oncology at H. Lee Moffitt Cancer Center, discusses the importance of real-world data for treating small cell lung cancer. Moderated by Misty Shields, MD, PhD, IU Health, and LUNGevity’s Ann Fish-Steagall, RN, BSN, SVP of Patient Services and Health Care Delivery, the monthly Small Cell SMASHERS series highlights the latest discoveries and breakthroughs for SCLC.

As tobacco use has declined in recent years, we have seen a new demographic of lung cancer patients emerge. Lung cancer in individuals who have never smoked (LCINS) is becoming more common. These people are often younger women with no history of tobacco exposure. Researchers are working to understand the needs of this growing population by identifying other risk factors for lung cancer, such as family history and environmental exposures. They are also studying the molecular underpinnings of this disease to develop targeted approaches for early detection and treatment. As part of LUNGevity’s

Read time: 6 minutes. April turned out to be an exciting month for lung cancer science. First, we attended the 2025 Small Cell Lung Cancer (SCLC) Hot Topic Meeting held in New York from April 2-4, then the American Association for Cancer Research (AACR) Annual Meeting in Chicago from April 24-30. The SCLC Hot Topic Meeting, hosted by the International Association for the Study of Lung Cancer, has become one of our favorite science meetings. Held at the Memorial Sloan Kettering Cancer Center in New York, the meeting is one of a kind. It brings together scientists conducting preclinical research

The LUNGevity Conversations that Count speaker series offers an opportunity to stay informed, engage in critical discussions, and learn from top experts revolutionizing lung cancer care for underserved populations. The series is intended for healthcare professionals, community health equity champions, and anyone interested in equitable access to healthcare. In February, we welcomed Randi Williams, PhD, MPH, of the Lombardi Comprehensive Cancer Center at Georgetown University Medical Center. Her research focuses on methods to promote the adoption of evidence-based lung cancer control practices